Together , cohorts @ and @ included phe@del CFTR homozygous and heterozygous patients , randomly assigned to either @ days of lumacaftor ( cohort @ : @ mg , @ mg , or @ mg once per day , cohort @ : @ mg every @ h ) with ivacaftor @ mg every @ h added after @ days , or @ days of placebo .